Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 18/20 | 0.88 |
| ▸ | BCR | P11274 | 16/20 | 0.88 |
| ▸ | KIT | P10721 | 11/20 | 0.88 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.88 |
| ▸ | ABL2 | P42684 | 4/20 | 0.88 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.88 |
| ▸ | LYN | P07948 | 3/20 | 0.88 |
| ▸ | EGFR | P00533 | 2/20 | 0.88 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.88 |
| ▸ | LCK | P06239 | 2/20 | 0.88 |
| ▸ | FYN | P06241 | 2/20 | 0.88 |
| ▸ | CSF1R | P07333 | 2/20 | 0.88 |
| ▸ | FGR | P09769 | 2/20 | 0.88 |
| ▸ | SRC | P12931 | 2/20 | 0.88 |
| ▸ | BRAF | P15056 | 2/20 | 0.88 |
| ▸ | NQO2 | P16083 | 2/20 | 0.88 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.88 |
| ▸ | FRK | P42685 | 2/20 | 0.88 |
| ▸ | BLK | P51451 | 2/20 | 0.88 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Masitinib SCHEMBL717239 | 0.93 | ABL1 (1.00) | ABL1BCRKITPDGFRAABL2 | |
| Masitinib SCHEMBL29355443 | 0.93 | ABL1 (1.00) | ABL1BCRKITPDGFRAABL2 | |
| Masitinib SCHEMBL29353195 | 0.93 | ABL1 (1.00) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL16085058 | 0.92 | ABL1 (0.89) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL717173 | 0.92 | ABL1 (0.88) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL26359118 | 0.91 | ABL1 (0.87) | ABL1BCRKITPDGFRAABL2 | |
| SCHEMBL717184 | 0.91 | ABL1 (0.87) | ABL1BCRKITPDGFRAABL2 | |
| Masitinib SCHEMBL1096348 | 0.91 | ABL1 (0.94) | ABL1BCRKITPDGFRAABL2 | |
| Masitinib SCHEMBL2297143 | 0.91 | ABL1 (0.94) | ABL1BCRKITPDGFRAABL2 | |
| Masitinib SCHEMBL30024483 | 0.91 | ABL1 (0.94) | ABL1BCRKITPDGFRAABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290235-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290235-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | DCK, ADK, DTYMK | ABL1 136/4885BCR 1534/4885KIT 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.